Altered function of selectin glycoprotein adhesion molecules may modulate severity and organ-specific manifestations of autoimmune and inflammatory disease via changes in leukocyte trafficking. Serum concentrations of selectin molecules have been suggested as useful biomarkers in systemic lupus erythematosus (SLE). We identified increased levels of soluble L-selectin (sL-selectin), but not soluble E-selectin (sE-selectin) in 278 European-Caucasian lupus patients compared to 230 healthy siblings (P ¼ 0.002). sL-selectin levels were markedly elevated in patients with IgG antiphospholipid autoantibodies (P ¼ 0.002), suggesting that perhaps sL-selectin defines a subgroup of lupus with vasculopathy. sL-selectin level was also influenced by two L-selectin polymorphisms: 665C4T, F206L in the epidermal growth factor-like domain (P ¼ 0.015) and rs12938 in the 3 0 -untranslated region (P ¼ 0.06). Having shown increased sL-selectin levels in lupus patients, we used genetics to investigate whether this was a secondary phenomena or the result of an underlying genetic mechanism. The inheritance of nine single-nucleotide polymorphisms (SNP) spanning the selectin locus was tested in 523 UK simplex SLE families. No association with SLE, or related phenotypes, was evident with any single SNP, or haplotype in family-based tests of association. Selectin polymorphisms are, therefore, unlikely to be independent factors in SLE susceptibility.
Introduction
Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, has protean clinical manifestations, including potentially fatal involvement of the kidneys (glomerulonephritis) and central nervous system. The hallmark of SLE is the presence of antibodies against components of the cell nucleus including chromatin and double-stranded DNA (dsDNA) and antibodies to membrane phospholipid. 1 The aetiology of SLE remains poorly understood, although it seems certain to include an interaction between hormonal and environmental factors and a significant genetic predisposition.
Since selectin glycoprotein cell adhesion molecules mediate the initial capture of leucocytes on vascular endothelium, 2 aberrant function of these molecules has the potential to alter leucocyte recruitment and hence organ-specific manifestations or severity of autoimmune disease. Selectins share a common structure, divided into N-terminal domain, epidermal growth factor (EGF)-like domain, lectin (ligand-binding) domain, variable short consensus repeats and transmembrane domains. Lselectin expression is constitutive on the majority of leucocytes, 3 but E-selectin is only present on activated endothelium and can be detected at sites of inflammation such as the rheumatoid joint 4 and atherosclerotic lesions. 5 Studies in knockout mice indicate that L-selectin has a general role in leucocyte trafficking, 6 while Eselectin is probably important in slow rolling and arrest of leucocytes in cytokine-stimulated endothelium. 7, 8 Selectin proteins may be useful biomarkers in SLE and perhaps contribute to the disease process. Small-scale studies in lupus patients indicate that levels of soluble and membrane-bound E-selectin 9, 10 and soluble L-selectin (sL-selectin) may be associated with SLE and disease activity. 11, 12 The sL-selectin is derived from calcium-dependent endoproteolytic cleaving of membrane-bound protein from activated lymphocytes and from rolling neutrophils. 13, 14 sL-selectin is present at high concentrations in the serum of healthy humans (B1.0 mg/ml) and retains functional activity perhaps inhibiting interactions involving its cell surface counterpart. 15 Physiological levels of sL-selectin may reduce lymphocyte migration to peripheral lymph nodes by 30%. 16 sE-selectin is also present in serum but at low concentrations. 17 Although a clear physiological role for this protein has not been defined, sE-selectin may be protective against murine nephritis.
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Genome-wide linkage studies indicate that SLE is inherited as a complex trait. [19] [20] [21] [22] [23] The genes encoding the selectins cluster to a 160 kb segment of human chromosome (1q24.2), within an SLE susceptibility interval 1q23-24, that has been linked with disease in ethnically diverse populations. 19, 22 This interval is orthologous to a region on distal mouse chromosome 1 24 that is known to contain several susceptibility intervals to murine lupus (reviewed in Vyse and Kotzin 25 ). Exon 4 of the E-selectin gene (SELE) contains a functional polymorphism (rs5361, 561A4C) that has been associated with SLE in two cohorts of EuropeanCaucasian SLE patients 26 and is implicated in early and severe atherosclerosis, [27] [28] [29] which is an important late complication of SLE. 30 Several other SELE variants have been associated with atherosclerosis and are of interest in lupus susceptibility: rs3917401 (98G4T), in the 5 0 -untranslated region (UTR) and rs5355 (1839C4T), which specifies a nonconservative leucine for phenylalanine exchange at amino acid 554 (L554F), in the transmembrane domain. 28 Polymorphism of the fifth short consensus repeat domain (rs5359, 1518C4T) may contribute to susceptibility to a common form of glomerulonephritis. 31 The L-selectin gene (SELL) has not been studied in lupus or related connective tissue diseases as far as we are aware.
The physiological properties of the selectins, their known disease associations and the genomic location of their encoding genes make these molecules interesting candidates in SLE susceptibility. We have investigated the utility of soluble selectin proteins as biomarkers in SLE and tested for association of potentially functional polymorphisms SELE and SELL in sporadic SLE by conducting a family-based association study. We have also tested the hypothesis that genetic polymorphism at the selectin locus might contribute to SLE by influencing levels of the soluble proteins in SLE patients.
Methods

SLE families
We have established a large collection of UK simplex SLE families comprising genomic DNA and serum. The study cohort represents a random sample of 523 SLE families that have been described in detail elsewhere. 32 Serum from probands and their unaffected siblings was tested for the presence of antinuclear antibodies (ANA) antidsDNA antibodies, antibodies to extractable nuclear antigens (Ro, La, Sm and RNP) and IgG and IgM isotypes of anticardiolipin antibodies as described previously. 32 All patients satisfied the ACR classification criteria for SLE. 33 
SNP identification and verification
Four known SELE polymorphisms (98G4T, 561A4C, 1518C4T and 1839C4T) were selected because of reported disease associations identified by a PubMed search (www.ncbi.nlm.nih.gov/entrez/). SNPs spanning SELL and the 3 0 portion of SELE were identified from publicly available databases: dbSNP (www.ncbi.nlm. nih.gov/SNP) and The SNP Consortium (http:// snp.cshl.org). The location of these SNPs is illustrated in Figure 1 . All SNPs were verified by direct sequencing of PCR product amplified from 90 chromosomes of diverse ethnicity. The primers and PCR conditions used are available on request.
Genotyping methods PCR-restriction fragment length polymorphism (PCR-RFLP). The PCR-RFLP assays used in this study are summarised in Table 1 . rs3917401 (98G4T) was genotyped in a manner similar to Zheng et al, 34 and rs5361 (561A4C) as described by El Magadmi et al. 26 Novel PCR-RFLP assays for rs5368 (1518C4T) and rs5359 polymorphisms were developed using restriction maps generated using the EMBOSS sequencing software package (www.hgmp.mrc.ac.uk). PCR product was digested to completion in appropriate buffer according to the manufacturer's specifications. The resulting fragments were size separated by electrophoresis through 3% agarose or 10% polyacrylamide gels and visualised by ethidium bromide staining. Details of the conditions for genomic PCR and restriction digests are available on request. Taqman s assays were performed under standardised conditions (available on request). The relative fluorescence of each reporter dye was measured using an ABI PRISM 7700 Sequence Detection System and allelic discrimination was performed using the SDS software package (Applied Biosystems, Warrington, UK).
Fine mapping of the 3
0 portion of SELL. To fine map the 3 0 -end of SELL, five additional SNPs were genotyped using Sequenomt mass spectrometry: two in intron 7 (rs2298899, rs2298900), two in intron 8 (rs2223286, rs2298901) and one in the 3 0 -UTR (rs7553).
Measurement of soluble selectin proteins. The sera from a subset of 299 European-Caucasian SLE patients and 230 healthy siblings were assayed for sE-and sL-selectin in duplicate using commercial sandwich ELISA kits (R&D Systems, Abingdon, Oxford, UK) without modification. The concentration of substrate was measured at 450 nm on a microplate spectrophotometer (Titretek Multiscan MCC/340, Life Sciences International) and concentrations of sE-and sL-selectin were generated from commercial standards using GraphPad Prism 3.03 (GraphPad Software, CA, USA).
Statistical analysis. Selectin E and L data were inspected graphically and by summary statistics (Table 1 and Figure 2 ). Since selectin E was positively skewed, a log e transformation was applied. For further analyses within pairs of siblings, a random-effect GLS model was fitted to allow for clustering within families. Each SNP was tested for a possible association with sE-or sL-selectin level. Effect modifiers of interest were gender and affection status. In a last step, several informative SNPs were tested in a multivariable model. Age was treated as an a priori confounder and parental genotype was also controlled for. A P-value of o0.05 in the latter was interpreted as significant. Genotype data were empirically examined for inconsistencies and tested using the pedigree checking program within TRANSMIT v2.5. 35 Expaternity pedigrees were excluded from all subsequent stages of analysis. The allele frequencies in each ethnic group were calculated in the untransmitted parental chromosomes (representing a random sample of the general population and compared using the w 2 statistic). The Each SNP was defined by its dbSNP nomenclature, nucleotide position in mRNA (SELE, accession NM_000450; SELL, accession NM_000655) and the genomic contig NT_034405. Amino-acid changes of nonsynonymous mutations and the location of the SNP within functional domains of the genes are described in columns 5 and 6. Allele frequencies (columns 7-9) were calculated in the parental chromosomes from the European-Caucasian (E), Indo-Asian (IA) and Afro-Caribbean (AF) populations (1240, 98 and 80 chromosomes, respectively). Those SNPs prevalent at significantly different frequencies between ethnic groups (Po0.01) are marked with an asterisk. All polymorphisms were in Hardy-Weinberg equilibrium (P-values in column 10). presence of haplotype blocks and the pattern of linkage disequilibrium (LD) across candidate genes, and the whole locus, were defined in the European-Caucasian group using haplotype frequencies obtained from TRANSMIT analysis and from an estimation of D 0 .
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Power calculations were performed based on the methods described by Risch and Merikangas. 37 Genotype data from SLE families were analysed by application of two family-based tests of association. The transmission disequilibrium test (TDT) was performed using the computer program TRANSMIT v2.5, which is powerful in reconstruction of missing parental genotype. 38 Transmission of single markers was examined in addition to haplotype analysis. The information provided by each SLE family was maximised by including genotype data from siblings in the pedigree disequilibrium test (PDT) version 3.12, 39 which integrates information from pedigrees irrespective of structure and size.
A diagnosis of SLE was used to define affection, but families were also stratified for ethnicity, the presence of renal involvement and ANA profile. The presence of autoantibodies was observed to cluster in families (manuscript in preparation) with multiple autoantibody-positive siblings present in many families. Therefore, in the latter analysis, TRANSMIT was constrained to select a single affected individual from each family at random. Multiple iterations of TRANSMIT were performed and the w 2 values obtained for each SNP and their distribution was tested using the PRISM software package. In the presence of a normal distribution, the arithmetic mean of the w 2 values was then used to derive the point P-value for this analysis.
Results
The SNPs employed to map the SELE and SELL genes are summarised in Figure 1 and Table 1 . Four coding SNPs in SELE were selected because of reported disease associations; the inclusion of rs5359 in the 3 0 -UTR maximised the coverage of the gene. Four SELL SNPs were prioritised by potential function and location. All SNPs were in Hardy-Weinberg equilibrium in the three main ethnic groupings tested. Ethnicity was observed to influence the distribution of SNPs in the 3 0 portion of SELE and the 5 0 part of SELL: the minor allele frequency of rs5355, rs5359 and rs2205849 was greater in the IndoAsian population than in European Caucasians, while in Afro-Caribbean parents, rs5355 was absent (Table 1) .
LD and haplotype analysis
There was restricted haplotype diversity ( Figure 1 ) and strong LD both within the SELE and SELL genes and across the locus as a whole (spanning 42 kb of DNA). In European-Caucasian individuals, strong LD existed between all markers examined with D 0 40.9; seven haplotypes constitute 97% of those observed in Eur- (Figure 1) . The genotypes of the 5 0 SELE SNPs rs3917401 (98G4T) and rs5361 (561A4C) were redundant in all three major racial groups studied. In European-Caucasian families, the minor alleles of SNPs between rs5368 and rs3177980 (spanning 20 kb) were not found on any other haplotypes. The extent of LD in Indo-Asian and Afro-Caribbean individuals was broadly similar to that identified in European-Caucasians, although LD may weaken at the 3 0 limit of the locus (D 0 ¼ 0.04-0.45) (data not shown).
E-and L-selectin polymorphism in SLE
Soluble selectin protein levels in SLE probands and sibling controls Levels of soluble selectin proteins were measured in serum from a subset of 299 European-Caucasian families (299 probands and 230 healthy siblings) as they had been previously typed for levels of the acute phase reactant, C-reactive protein (CRP). 32 This allowed the exclusion of those individuals with a potentially confounding intercurrent acute phase response (defined as CRP levels above 10 mg/l, the accepted upper limit of normal). In all, 278 probands (257 females and 21 males) and 230 siblings (141 females and 89 males) were available for analysis.
Levels of sL-selectin were higher in female siblings (mean 1165 ng/ml) compared to males (mean 1089 ng/ ml; see Table 2 and Figure 2 ). Modelling the effects of both affection status and sex on sL-selectin, in a GLS random-effects model, we found lupus patients to have a significantly higher serum level of protein than their unaffected siblings in crude (P ¼ 0.002) and sex-adjusted analysis (P ¼ 0.02), whereas gender was not predictive in the adjusted model (P ¼ 0.19). We sought to determine whether sL-selectin was a useful biomarker for any clinical or serological SLE phenotypes. Taking account of clustering in families, there seemed to be no effect of the presence of renal disease in SLE probands on sL-selectin levels. However, after adjustment for age, sex and affection status, we found evidence that lower levels of sL-selectin were present in those with a history of lupus nephritis (P ¼ 0.009). This suggested that within SLE patients without a history of nephritis that a subgroup would exhibit elevated L-selectin. We considered patients with secondary Sjö gren's syndrome and antiphospholipid syndrome and related serologic phenotypes. We found an association between IgG anticardiolipin antibody (IgG-ACA) production and sL-selectin; on crude analysis, patients with raised IgG-ACA had higher selectin levels (Po0.0001). The association remained when age, sex and affection status were taken into account (P ¼ 0.0002). There was no evidence for a correlation between sL-selectin and IgM-ACA.
There was also a marked effect of gender on the mean levels of sE-selectin level, which were 24% lower in females compared to males (Po0.001) independent of affection status. Although sE-selectin levels were marginally lower in lupus patients compared to their unaffected siblings (P ¼ 0.09), this did not persist when adjusted for sex (P ¼ 0.96). There was no association between sE-selectin levels and renal disease or Sjö gren's syndrome and antiphospholipid syndrome or any of the serological traits.
The effect of selectin genotype on soluble selectin levels In single SNP analysis comparing sL-selectin levels and genotype, there was a significant effect from SNPs rs3177980, rs964555 and rs12938 ( Table 3) . As these polymorphisms are haplotype-tagging SNPs (Figure 1) , the putative causative SNP in this association (rs3177980) could be determined by constructing models containing rs3177980, rs964555 and rs12938 with further adjustments for sex, affection status and age ( Table 3 ). The rs3177980 genotype, which underlies the F206L change, was significantly associated with sL-selectin levels in all models. There was also a suggestion of interaction In this table, the effect of SELL polymorphism on sL-selectin levels was investigated using data pooled from probands (n ¼ 278) and healthy siblings (n ¼ 230). Effects were modelled adjusting for each SNP (Model 1), plus gender (Model 2). Model 3 adjusts for affection status, parental genotype and renal lupus in addition to gender. A significant effect was evident from rs3177980 regardless of the model used.
between rs12938, in the 3 0 -UTR of the gene and female gender (P ¼ 0.06), after adjustment for affection status and age. To determine whether any related SNP at the 3 0 -end of SELL would strengthen the association an additional five SNPs between intron 7 and the 3 0 -UTR were genotyped. Each SNP was a singleton, identifying a unique haplotype; none were associated with sL-selectin levels. There was no evidence for a significant effect of any SNP tested with sE-selectin expression within crude or adjusted analyses (data not shown).
Family-based tests of association
Since SELL genotype influenced levels of the sL-selectin protein, which we had shown to be elevated in SLE patients, we hypothesised an association between selectin polymorphism and SLE. The selectin genotypes of 523 SLE families were examined for association with disease by the TDT (TRANSMIT v2.5) and the PDT. However, in our lupus families, we were unable to identify an association between SLE and any single SNP or haplotype at the selectin locus (data from the European-Caucasian families is listed in Table 4 ). Further analysis excluded association with nephritis or autoantibody profile, including ACA production.
Discussion
Serum levels of sL-selectin were significantly elevated in our SLE patients compared to healthy siblings consistent with the work of others. 40 Previous studies have not detailed whether soluble selectin levels may demarcate a particular SLE subgroup. In our patients, we found that lower levels of sL-selectin were detectable in those with a history of lupus nephritis, whereas higher levels of sLselectin were found in patients who produced clinically significant amounts of IgG-ACA. The measurement of this protein in clinical practice may therefore serve as an additional biomarker in the diagnosis and monitoring of lupus patients. However, the impact of factors other than disease status, particularly at the genetic level, must first be appreciated for meaningful interpretation of such measurements. Accordingly, we addressed the effect of selectin genotype on sL-selectin levels in both lupus patients and their healthy siblings, and identified effects from two SNPs in SELL. In both groups, there was a significant effect evident from rs3177980. This C to T transition at nucleotide 665 of SELL mRNA specifies a non-conservative phenylalanine to leucine exchange at residue 206 of the mature protein. Although this SNP may not be causative, its position in the EGF-like domain may cause altered ligand binding, analogous to the 561A4C (S128R) variant in SELE, that enhances leukocyte tethering and firm adhesion to endothelium in vivo. 41, 42 We considered two possible explanations for this association.
(1) The amount of sL-selectin is influenced by the polymorphism. An effect on the quantity of soluble protein suggests an additional effect on transcriptional regulation, post-translational processing or altered efficiency of endoproteolytic cleavage of L-selectin from the cell surface. (2) The binding of the antibody used in the sL-selectin assay was affected by the F206L change. The epitope on L-selectin that the antibody binds to in this assay appears to be unknown and hence we could not extract this information from R&D Systems.
A second polymorphism, rs12938, located in the 3 0 -UTR may also exert a weak effect on sL-selectin expression perhaps by influencing mRNA stability, 43 in an effect that may interact with female gender. An in silico investigation using utr.scan (http://bigarea.area.-ba.cnr.it: 800/EmbIT/UTRHome) did not identify any determinants of transcript stability within the nucleotide sequence surrounding rs12938, and in particular no sex hormone responsive motifs that would account for the effect of gender. No coding polymorphisms are known between rs3177980 and rs12938 (www.ncbi.nlm.nih.gov/ LocusLink/); however, LD with unknown polymorphisms in distant regulatory sites cannot be excluded.
A genetics approach was used to determine whether sL-selectin plays a primary role in lupus pathogenesis. That is say, we sought to distinguish the possibilities that ) are given with one degree of freedom. SNP analysis by PDT is listed in columns 5 and 6. Data from all available family members (triads and discordant siblings) were included in this analysis (TDO parameter setting). Statistical analysis was as a global chi square (w 2 ), using the 'sum' setting in which all pedigrees received equal weighting independent of size.
(1) there is a shared genetic basis between sL-selectin levels and SLE and (2) that altered soluble levels are a consequence of the disease. Although SLE patients had elevated levels of sL-selectin, neither rs3177980 nor rs12938 was associated with SLE in our cohort, suggesting that this may be a secondary phenomenon perhaps related to chronic immune activation. We also examined the inheritance of other coding and regulatory polymorphisms in SELE and SELL that have been implicated in SLE, 26 atherosclerosis 27,29 and glomerulonephritis. 31 We found no association between rs5361 (561A4C) and SLE or renal involvement, which defines patients at the severe end of the lupus spectrum. Given the power of our study, this suggests that any effect of this polymorphism on SLE must be absent or slight. No other selectin haplotype or single SNP was associated with SLE or any subgroup. Although rs5359 (1518C4T) has been associated with IgA nephropathy, 31 our negative results in lupus nephritis suggest that this may not act as a common susceptibility polymorphism to renal inflammation. LD was consistently strong across this locus in European-Caucasians, with D 0 values that approached unity, and haplotype diversity was restricted. Hence, it is unlikely that aetiological polymorphisms located between markers have been missed. We note that LD was particularly marked in the 5 0 portion of the gene, such that rs3917401 (98G4T) and rs5361 (561A4C) were redundant for genotyping purposes, contradicting claims that these SNPs are independently associated with early atherosclerosis. 27, 29, 34 sE-selectin has been proposed as a prognostic marker in SLE. 10 There was no association between sE-selectin levels and the diagnosis of SLE per se or related phenotypes in our patients, consistent with the negative data reported in systemic disease by others. 12, 44, 45 Taken together, with the negative results of the genetic study, this we conclude that E-selectin is not of obligate component of the disease process in SLE. Selectin polymorphisms did not appear to influence sE-selectin levels in either sibling controls or lupus patients. In particular, there was no effect of the 561A4C polymorphism in contrast to a weak association reported in UK patients with type 2 diabetes mellitus. 46 This may be a population or disease-specific association.
We suggest that sL-selectin may represent a valuable biomarker in SLE. However, the interpretation of these levels is complicated by genetic variation in at the SELL locus. The absence of genetic association of SELL polymorphism with SLE suggests that the elevation of sL-selectin in SLE is a secondary consequence of disease. Interestingly, sL-selectin may not be a mere bystander in lupus as the soluble form of the molecule has been shown to be functional; for example, it can inhibit lymphocyte migration to peripheral lymph nodes. 15, 16 Indeed, abnormal sL-selectin level may predict patients who develop pulmonary inflammation 47, 48 and vascular disease including pulmonary hypertension, 49 and ischaemic heart disease. 50 The association of sL-selectin with IgG-ACA in our patients suggests that the soluble molecule may serve as a marker for vascular risk in SLE, and studies are planned to explore this possibility.
In conclusion, allelic variants within the SELE and SELL genes have been investigated as possible independent risk factors for SLE and no association was found with any SNPs tested. sL-selectin is a potentially valuable biomarker in SLE, but such data must be interpreted in the light of selectin genotype since two polymorphisms in the 3 0 portion of the SELL gene were found to influence serum sL-selectin level. The potential value of biomarkers in disease should always be considered in the light of genetic factors that may impact on them when making inter-individual comparisons.
